File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial

TitleEffect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trial
Authors
Issue Date2003
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805 How to Cite?
AbstractBackground: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.
Persistent Identifierhttp://hdl.handle.net/10722/91583
ISSN
2014 Impact Factor: 5.727
2013 SCImago Journal Rankings: 2.609
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, KCen_HK
dc.contributor.authorLau, CSen_HK
dc.contributor.authorIp, WYen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorWong, RWMen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-17T10:21:44Z-
dc.date.available2010-09-17T10:21:44Z-
dc.date.issued2003en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2003, v. 17 n. 6, p. 799-805en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91583-
dc.description.abstractBackground: There is controversy as to whether Helicobacter pylori and non-steroidal anti-inflammatory drugs interact to cause peptic ulcers. Aim: To study whether the eradication of H. pylori in patients on long-term non-steroidal anti-inflammatory drug therapy prevents the development of ulcers. Methods: Patients infected with H. pylori whilst receiving long-term non-steroidal anti-inflammatory drug therapy, but with no ulcers at baseline endoscopy, were randomized to receive either triple antibiotic therapy (metronidazole 300 mg, clarithromycin 250 mg and amoxicillin 500 mg, given four times daily: n = 70) or placebo (n = 70) for 2 weeks. Non-steroidal anti-inflammatory drugs were continued throughout the study period. Endoscopy was repeated 12 weeks after the end of treatment. The development of ulcers was compared between the two groups. Results: Endoscopy at 12 weeks revealed peptic ulcer development in five [7%; 95% confidence interval (CI), 2-16] of the patients who received triple therapy and in six (9%; 95% CI, 3-18) of those who received placebo (P = 1.00). No significant difference in the development of ulcers was found between patients with persistent H. pylori infection (7/80; 9%; 95% CI, 4-17) and those with the eradication of H. pylori (4/52; 8%; 95% CI, 2-19) (P = 1.00). Conclusions: The eradication of H. pylori in patients receiving long-term treatment with non-steroidal anti-inflammatory drugs did not prevent ulcer development. However, because the rate of ulcer development was low, a study with a larger sample size is required to confirm this finding.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAmoxicillin - therapeutic useen_HK
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - therapeutic useen_HK
dc.subject.meshClarithromycin - therapeutic useen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshDrug Therapy, Combination - therapeutic useen_HK
dc.subject.meshDuodenal Ulcer - prevention & controlen_HK
dc.subject.meshDyspepsia - etiologyen_HK
dc.subject.meshEndoscopy, Gastrointestinalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHelicobacter Infections - drug therapyen_HK
dc.subject.meshHelicobacter pylorien_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetronidazole - therapeutic useen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshStomach Ulcer - prevention & controlen_HK
dc.titleEffect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: A double-blind, placebo-controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.emailLau, CS:cslau@hku.hken_HK
dc.identifier.emailIp, WY:wyip@hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.identifier.authorityIp, WY=rp00401en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2003.01528.xen_HK
dc.identifier.pmid12641502-
dc.identifier.scopuseid_2-s2.0-0037444981en_HK
dc.identifier.hkuros81290-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037444981&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue6en_HK
dc.identifier.spage799en_HK
dc.identifier.epage805en_HK
dc.identifier.isiWOS:000181634100007-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.scopusauthoridIp, WY=35549641700en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridWong, RWM=16945028500en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats